News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
286,751 Results
Type
Article (15210)
Company Profile (298)
Press Release (271235)
Multimedia
Podcasts (96)
Webinars (12)
Section
Business (80030)
Career Advice (167)
Deals (13395)
Drug Delivery (43)
Drug Development (50829)
Employer Resources (31)
FDA (5899)
Job Trends (5191)
News (145469)
Policy (10094)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Standard (3)
Academia (945)
Accelerated approval (25)
Adcomms (14)
Allergies (99)
Alliances (21769)
ALS (157)
Alzheimer's disease (1113)
Antibody-drug conjugate (ADC) (353)
Approvals (6155)
Artificial intelligence (337)
Autoimmune disease (212)
Automation (10)
Bankruptcy (105)
Best Places to Work (4567)
BIOSECURE Act (6)
Biosimilars (117)
Biotechnology (230)
Bladder cancer (117)
Brain cancer (57)
Breast cancer (404)
Cancer (3778)
Cardiovascular disease (277)
Career advice (154)
Career pathing (8)
CAR-T (255)
CDC (7)
Celiac Disease (1)
Cell therapy (671)
Cervical cancer (21)
Clinical research (44564)
Collaboration (1396)
Company closure (3)
Compensation (716)
Complete response letters (54)
COVID-19 (1120)
CRISPR (103)
C-suite (718)
Cystic fibrosis (117)
Data (5318)
Denatured (21)
Depression (109)
Dermatology (48)
Diabetes (296)
Diagnostics (1429)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (245)
Drug pricing (52)
Drug shortages (3)
Duchenne muscular dystrophy (263)
Earnings (32491)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (52937)
Executive appointments (676)
FDA (7978)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1149)
Gene editing (218)
Generative AI (29)
Gene therapy (580)
GLP-1 (552)
Government (1181)
Grass and pollen (3)
Guidances (172)
Healthcare (6699)
HIV (26)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (83)
Immunology and inflammation (228)
Immuno-oncology (69)
Indications (120)
Infectious disease (1265)
Inflammatory bowel disease (181)
Inflation Reduction Act (10)
Influenza (54)
Intellectual property (195)
Interviews (19)
IPO (7368)
IRA (13)
Job creations (868)
Job search strategy (133)
JPM (41)
Kidney cancer (9)
Labor market (27)
Layoffs (250)
Leadership (12)
Legal (1405)
Liver cancer (44)
Longevity (23)
Lung cancer (497)
Lymphoma (282)
Machine learning (33)
Management (7)
Manufacturing (479)
MASH (152)
Medical device (2703)
Medtech (2718)
Mergers & acquisitions (6736)
Metabolic disorders (854)
mRNA (146)
Multiple sclerosis (119)
NASH (14)
Neurodegenerative disease (298)
Neuropsychiatric disorders (81)
Neuroscience (2214)
Neurotech (1)
NextGen: Class of 2026 (2049)
Non-profit (880)
Now hiring (38)
Obesity (385)
Opinion (138)
Ovarian cancer (167)
Pain (128)
Pancreatic cancer (205)
Parkinson's disease (280)
Partnered (12)
Patents (368)
Patient recruitment (467)
Peanut (46)
People (27091)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15789)
Phase 2 (20742)
Phase 3 (13069)
Pipeline (5178)
Policy (103)
Postmarket research (854)
Preclinical (6714)
Press Release (30)
Prostate cancer (183)
Psychedelics (58)
Radiopharmaceuticals (270)
Rare diseases (823)
Real estate (1455)
Recruiting (12)
Regulatory (10407)
Reports (20)
Research institute (986)
Resumes & cover letters (20)
Rett syndrome (32)
RNA editing (25)
RSV (24)
Schizophrenia (144)
Series A (225)
Series B (155)
Service/supplier (1)
Sickle cell disease (89)
Special edition (19)
Spinal muscular atrophy (124)
Sponsored (17)
Startups (2026)
State (1)
Stomach cancer (5)
Supply chain (38)
Tariffs (19)
The Weekly (73)
Vaccines (383)
Venture capital (84)
Weight loss (205)
Women's health (42)
Worklife (2)
Date
Today (111)
Last 7 days (525)
Last 30 days (1832)
Last 365 days (18039)
2026 (6495)
2025 (18104)
2024 (20557)
2023 (22432)
2022 (26857)
2021 (27834)
2020 (23388)
2019 (16261)
2018 (11756)
2017 (13760)
2016 (11851)
2015 (14365)
2014 (10407)
2013 (7488)
2012 (7540)
2011 (7623)
2010 (7448)
Location
Africa (154)
Alabama (71)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18563)
Australia (3185)
California (8145)
Canada (2100)
China (936)
Colorado (293)
Connecticut (308)
Delaware (277)
Europe (39889)
Florida (1040)
Georgia (239)
Hawaii (2)
Idaho (17)
Illinois (475)
India (43)
Indiana (191)
Iowa (8)
Japan (279)
Kansas (82)
Kentucky (11)
Louisiana (12)
Maine (26)
Maryland (848)
Massachusetts (6446)
Michigan (123)
Minnesota (288)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (43)
New Hampshire (22)
New Jersey (1868)
New Mexico (13)
New York (2025)
North Carolina (949)
North Dakota (6)
Northern California (4095)
Ohio (205)
Oklahoma (11)
Oregon (23)
Pennsylvania (1500)
Puerto Rico (11)
Rhode Island (27)
South America (216)
South Carolina (12)
Southern California (3259)
Tennessee (49)
Texas (1089)
United States (26921)
Utah (112)
Virginia (169)
Washington D.C. (37)
Washington State (670)
West Virginia (1)
Wisconsin (53)
286,751 Results for "maze therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.
March 25, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
·
5 min read
Press Releases
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
·
11 min read
Press Releases
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
·
1 min read
Press Releases
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
·
1 min read
Press Releases
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
1 min read
Press Releases
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
·
8 min read
Press Releases
Maze Therapeutics to Participate in Four Upcoming Investor Conferences - November 4, 2025
November 5, 2025
·
1 min read
Press Releases
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 6, 2025
·
10 min read
Press Releases
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
October 6, 2025
·
6 min read
1 of 28,676
Next
